Literature DB >> 23633159

A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival.

Yong-bing Wu1, You-sheng Huang, Ya-ping Xu, Yu-fang Sun, Dong-liang Yu, Xiao-qiang Zhang, Xiang Long, Shu-qiang Zhu, Jiang-liang Zhou, Jian-jun Xu.   

Abstract

PURPOSE: We investigated expression of TM4SF5 and its involvement in human esophageal cancer (HEC).
METHODS: We analyzed TM4SF5 expression in normal esophageal epithelial cells (HEEC), in four HEC cell lines, and in 20 HEC clinical tissue samples and matched nontumor samples. The effect of TM4SF5 on HEC cell proliferation and metastasis and invasion was assessed, and the relationship between TM4SF5 and integrin β1 was determined. Finally, TM4SF5 and integrin β1 expression were further examined by use of immunohistochemistry (IHC) and tissue microarray analysis, and the prognostic use of TM4SF5 and integrin β1 in HEC was evaluated.
RESULTS: TM4SF5 was more highly expressed in HEC cells and in HEC tissues than in HEEC and matched nontumor tissues. Down-regulation of TM4SF5 in KYSE150 cells reduced cell proliferation and metastasis and invasion whereas metastasis and invasion by KYSE510 increased after TM4SF5 cDNA transfection. In HEC cells, TM4SF5 formed a complex with integrin β1, and interference with integrin β1 in KYSE510-TM4SF5 cells markedly inhibited cell invasion on laminin 5. Our findings also showed that TM4SF5 and integrin β1 overexpression correlated with low differentiation and high stage (p<0.05, respectively). Postoperative 5-year overall survival of patients with TM4SF5low and/or integrin β1low was higher than for patients with TM4SF5high and/or integrin β1high. Multivariate analysis demonstrated that TM4SF5 and integrin β1 co-overexpression was an independent prognostic marker for HEC.
CONCLUSION: TM4SF5 is positively associated with HEC invasiveness. The combination of TM4SF5 with integrin β1 could potentially serve as a novel marker for predicting HEC prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23633159     DOI: 10.1007/s10620-013-2690-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Functional domains in tetraspanin proteins.

Authors:  Christopher S Stipp; Tatiana V Kolesnikova; Martin E Hemler
Journal:  Trends Biochem Sci       Date:  2003-02       Impact factor: 13.807

Review 2.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

3.  Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative.

Authors:  Sin-Ae Lee; Hyung Won Ryu; Young Mee Kim; Suyong Choi; Mi Ji Lee; Tae Kyoung Kwak; Hyeon Jung Kim; Moonjae Cho; Ki Hun Park; Jung Weon Lee
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 4.  Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes.

Authors:  María Yáñez-Mó; Olga Barreiro; Mónica Gordon-Alonso; Mónica Sala-Valdés; Francisco Sánchez-Madrid
Journal:  Trends Cell Biol       Date:  2009-08-24       Impact factor: 20.808

5.  The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment.

Authors:  Sin-Ae Lee; Young Mee Kim; Tae Kyoung Kwak; Hyeon Jung Kim; Semi Kim; Wonil Ko; Sung-Hoon Kim; Ki Hun Park; Hyun Jeong Kim; Moonjae Cho; Jung Weon Lee
Journal:  Carcinogenesis       Date:  2009-09-29       Impact factor: 4.944

6.  Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Authors:  Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 7.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

8.  Amount of expression of the tumor-associated antigen L6 gene and transmembrane 4 superfamily member 5 gene in gastric cancers and gastric mucosa.

Authors:  R Kaneko; N Tsuji; C Kamagata; T Endoh; M Nakamura; D Kobayashi; A Yagihashi; N Watanabe
Journal:  Am J Gastroenterol       Date:  2001-12       Impact factor: 10.864

Review 9.  Targeting of tetraspanin proteins--potential benefits and strategies.

Authors:  Martin E Hemler
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin β1 complex in the progression of hepatocellular carcinoma.

Authors:  Ranjan Prasad Devbhandari; Guo-Ming Shi; Ai-Wu Ke; Fei-Zhen Wu; Xiao-Yong Huang; Xiao-Ying Wang; Ying-Hong Shi; Zhen-Bin Ding; Yang Xu; Zhi Dai; Jia Fan; Jian Zhou
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

View more
  8 in total

1.  Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues.

Authors:  Baojin Xu; Wu Lv; Xiaoyan Li; Lina Zhang; Jie Lin
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

2.  Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model.

Authors:  Young-Eun Kim; Sanghoon Kwon; Guang Wu; Dongbum Kim; Byoung Kwon Park; Jeong-A Park; Kyung-Chan Choi; Doo-Sik Kim; Hyung-Joo Kwon; Younghee Lee
Journal:  Oncotarget       Date:  2014-09-30

3.  Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity.

Authors:  Hye-Mi Ahn; Jihye Ryu; Jin Myeong Song; Yunhee Lee; Hye-Jin Kim; Dongjoon Ko; Inpyo Choi; Sang Jick Kim; Jung Weon Lee; Semi Kim
Journal:  Theranostics       Date:  2017-01-11       Impact factor: 11.556

4.  A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model.

Authors:  Sangkyu Park; Dongbum Kim; Guang Wu; Harry Jung; Jeong-A Park; Hyung-Joo Kwon; Younghee Lee
Journal:  Onco Targets Ther       Date:  2018-12-03       Impact factor: 4.147

5.  TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.

Authors:  Dian Xiong; Chun Jin; Xudong Ye; Baiquan Qiu; Xu Jianjun; Shuqiang Zhu; Long Xiang; Haibo Wu; Wu Yongbing
Journal:  Cancer Sci       Date:  2018-08-28       Impact factor: 6.716

6.  Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models.

Authors:  Dongjoon Ko; Eunmi Kim; Eun-Ae Shin; Seo Hee Nam; Junghwa Yoon; Jin-Sook Lee; Yunhee Lee; Sora Park; Kyungsoo Ha; So-Young Choi; Jung Weon Lee; Semi Kim
Journal:  Mol Ther Oncolytics       Date:  2022-01-31       Impact factor: 7.200

7.  Role of Integrin β1 in the progression and chemo-resistance of esophageal squamous cell carcinoma.

Authors:  Ying-Hua Xie; Li-Qiang Ran; Zhi-Yong Wu; Chun Sun; Xiu-E Xu; Hai-Ying Zou; Wang-Kai Fang; Jian-Jun Xie
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

Review 8.  Membrane Proteins Involved in Epithelial-Mesenchymal Transition and Tumor Invasion: Studies on TMPRSS4 and TM4SF5.

Authors:  Semi Kim; Jung Weon Lee
Journal:  Genomics Inform       Date:  2014-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.